Slovakia joins Centralised Evaluation of medicines

For the first time since joining the European Union, Slovakia will take part in centralised drug evaluation, according to State Institute for Drug Control (SUKL). It will be evaluating a generic drug containing Miglustat. It is used to treat mild to moderate type 1 Gaucher disease in adult patients. "We have already twice applied to join the centralised procedure. The third time it worked out. The key task associated with this is to build and develop professional capacities, which requires personnel and financial stability of the state institute," said SUKL director Zuzana Baťová.